Paris & New York, June 7, 2017
June 19th: Conference Call to Discuss Phase IIa Hypertension Data
June 27th: KOL and Investor Day in New York, NY
Quantum Genomics (Alternext - FR0011648971 - ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, is excited to confirm that it is hosting two significant events in the month of June.
On June 19th, Quantum Genomics will host a conference call followed by a question-and-answer session to discuss the phase IIa results for the drug candidate QGC001, which are being formally presented the day before at the 27th Meeting on Hypertensions and Cardiovascular Protection in Milan, Italy.
|Event:||Phase II Results Conference Call & Webcast|
|Date:||June 19, 2017|
|Time:||6:00 pm CET, 5:00pm GMT, 12:00pm ET|
|U.S. & Canada Dial-in:
On June 27th, Quantum Genomics will be holding a key opinion leader (KOL) day in New York, NY, that is open to the investment community. As a rem inder, this event will feature presentations by Dr. Henry Black, adjunct clinical professor of medicine and member of the section of cardiology at the New York University School of Medicine, and Dr. Keith Ferdinand, professor of medicine at Tulane University School of Medicine. In addition, Quantum Genomics' chairman and chief executive officer, Lionel Ségard, and chief medical officer, Dr. Bruno Besse, will comment on the phase IIa hypertension data and the upcoming clinical trial in the United States.
|Event:||Quantum Genomic KOL & Investor Day|
|Date:||June 27, 2017|
|Time:||11:00am – 2:00pm ET|
|Location:||Le Parker Meridien, 119 W. 56th Street, New York, NY 10019|
|RSVP Info:||Please send RSVP to Tirth Patel (email@example.com)|
A webcast of the event will be available on Quantum Genomics' website, www.quantum-genomics.com, shortly after the event ends, and will remain for 90 days.
Lionel Ségard, Chairman & CEO of Quantum Genomics, says:
“Quantum Genomics is excited to present its phase IIa clinical data and corporate update to investors on both sides of the Atlantic, and around the world, in a two-week span. We are at an important point in our company's history, and are eager to share it with the investment community.”
Chairman & Chief Executive Officer
+33 1 85 34 77 77
CFO – Investor Relations
+33 1 85 34 77 75
ACTUS finance & communication (Europe)
+33 1 53 67 36 73
Edison Advisors (U.S.)
+1 (646) 653-7035
ABOUT QUANTUM GENOMICS
Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially hypertension and heart failure.
The Company is developing a new therapeutic approach based on BAPAI (Brain Aminopeptidase A Inhibition). This is the result of more than 20 years of academic research in the laboratories of the Collège de France, INSERM, CNRS and the University of Paris Descartes.
Quantum Genomics is listed on the Alternext market in Paris (isin code FR0011648971, Ticker ALQGC).
The Company has offices in Paris, France, and New York, NY, USA. For more information, please visit www.quantum-genomics.com.